Provided by Tiger Trade Technology Pte. Ltd.

CARSGEN-B

12.600
+0.1501.20%
Volume:2.95M
Turnover:36.66M
Market Cap:7.48B
PE:-71.08
High:12.750
Open:12.680
Low:12.050
Close:12.450
52wk High:28.600
52wk Low:10.870
Shares:594.00M
HK Float Shares:594.00M
Volume Ratio:1.43
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.177
ROE:-9.57%
ROA:-8.91%
PB:5.82
PE(LYR):-71.08
PS:46.90

Loading ...

Movement Alert|CARsgen Therapeutics-B Falls 5.13% in Regular Trading, Strategic Pivot Away from Autologous CAR-T Pipeline Sparks Market Concerns

Market Focus
·
Jul 07

CARsgen Therapeutics (SEHK:2171) Is Up 20.8% After First Solid Tumor CAR T Approval - What's Changed

Simply Wall St.
·
Jul 04

Movement Alert|CARsgen Therapeutics-B Rises 5.14% in Regular Trading, Buyback Plan and Biotech Sector Strength Fuel Rebound

Market Focus
·
Jul 03

Movement Alert|CARsgen Therapeutics-B Rises 5.19% in Regular Trading, Buyback Plan and Sector Rally Continue to Support Rebound

Market Focus
·
Jul 02

Following Satri Cel Approval Is CARsgen Therapeutics Holdings (SEHK:2171) Fully Priced?

Simply Wall St.
·
Jun 30

Movement Alert|CARsgen Therapeutics-B Rises 6.31% in Regular Trading, Buyback Plan and Sector Recovery Fuel Rebound

Market Focus
·
Jun 29

CARSGEN-B Shares Surge in Afternoon Trading Following Share Buyback Plan Announcement

Stock News
·
Jun 26

Carsgen Therapeutics Climbs on Board Nod for Share Buyback

Reuters
·
Jun 26

CARSGEN-B Announces Share Buyback Plan of Up to 5% of Issued Shares

Stock News
·
Jun 26

Carsgen Therapeutics Holdings - Approves Share Repurchase Plan for up to 30.12 Mln Shares, About 5% of Issued Shares

THOMSON REUTERS
·
Jun 26

High Growth Tech Stocks In Asia To Watch For Potential Expansion

Simply Wall St.
·
Jun 26

Movement Alert|CARsgen Biotech Falls 5.07% in Regular Trading, Fourth Straight Decline After Global First Solid Tumor CAR-T Approval

Market Focus
·
Jun 26

Movement Alert|CARsgen Therapeutics Falls 5.46% in Regular Trading, Stock Under Pressure for Third Consecutive Day After Global First Solid Tumor CAR-T Approval

Market Focus
·
Jun 25

CARSGEN-B Secures World's First CAR-T Therapy for Solid Tumors, Faces Commercialization Test with 990,000 RMB Per Dose

Deep News
·
Jun 25

Movement Alert|CARsgen Therapeutics Falls 6.03% in Regular Trading, Stock Continues Selling Off Despite Historic Solid Tumor CAR-T Approval

Market Focus
·
Jun 24

Movement Alert|CARsgen Therapeutics Intraday Decline 7.49%, Profit-Taking After Historic Solid Tumor CAR-T Approval

Market Focus
·
Jun 23

CARsgen Announces Approval of Satri-Cel, the World's First Car T-Cell Therapy Product for Solid Tumors

THOMSON REUTERS
·
Jun 22

CARsgen Therapeutics Gets Nod for Gastric Cancer Drug Application in China

MT Newswires Live
·
Jun 22

CARsgen gains NMPA approval for satri-cel, the world’s first CAR T therapy targeting solid tumors

Bulletin Express
·
Jun 22

CARSGEN-B Receives NMPA Approval for Claudin18.2 CAR-T Therapy Kelimei®

Stock News
·
Jun 22